Aaron Kunzer

Aaron Kunzer is a Senior Medicinal Chemist in Oncology Discovery at AbbVie, where they specialize in fragment-based drug design and the development of antibody-drug conjugates. Kunzer has contributed significantly to cancer treatment as a pioneer of BCL-2 protein family inhibitors, including the first-in-class drug Venclexta™. With experience in leading chemistry teams and multiple significant patents, Kunzer's work has resulted in notable contributions to the field of medicinal chemistry, including several clinical compounds and recognized publications. They are currently pursuing a Master’s degree in Chemistry at DePaul University and hold two Bachelor's degrees in Mathematics and Chemistry from the University of Wisconsin-Madison.